{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:44:38Z","timestamp":1790660678436,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Posttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial to determine the safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and Wilms tumor 1 (WT1) messenger RNA (mRNA), after ASCT for MM. Ten patients received a priming immunization plus 2 boosters at 12, 30, and 90 days, respectively, after ASCT. Vaccines contained 9 \u00d7 106 mRNA-electroporated LCs. Ten additional patients did not receive LC vaccines but otherwise underwent identical ASCT and supportive care. At 3 months after ASCT, all patients started lenalidomide maintenance therapy. Vaccinated patients developed mild local delayed-type hypersensitivity reactions after booster vaccines, but no toxicities exceeded grade 1. At 1 and 3 months after vaccines, antigen-specific CD4 and CD8 T cells increased secretion of proinflammatory cytokines (interferon-\u03b3, interleukin-2, and tumor necrosis factor-\u03b1) above prevaccine levels, and also upregulated the cytotoxicity marker CD107a. CD4 and CD8 T-cell repertoire analysis showed a trend for increased clonal expansion in the vaccine cohort, which was more pronounced in the CD4 compartment. Although not powered to assess clinical efficacy, treatment responses favored the vaccine arm. Triple antigen\u2013bearing mRNA-electroporated autologous LC vaccination initiated at engraftment after ASCT, in conjunction with standard lenalidomide maintenance therapy for MM, is safe and induces antigen-specific immune reactivity. This trial was registered at www.clinicaltrials.gov as #NCT01995708.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005941","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T21:23:45Z","timestamp":1643664225000},"page":"1547-1558","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David J.","family":"Chung","sequence":"first","affiliation":[{"name":"Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, New York, NY;"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY;"},{"name":"The Rockefeller University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-2775","authenticated-orcid":false,"given":"Madhumitha","family":"Rangesa","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-3537","authenticated-orcid":false,"given":"Susan","family":"DeWolf","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4354-8864","authenticated-orcid":false,"given":"Yuval","family":"Elhanati","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlo","family":"Perica","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-6559","authenticated-orcid":false,"given":"James W.","family":"Young","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, New York, NY;"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY;"},{"name":"The Rockefeller University, New York, NY;"},{"name":"Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"1","key":"2022030416215479300_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin."},{"issue":"14","key":"2022030416215479300_B2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022030416215479300_B3","first-page":"705","article-title":"Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells","volume":"5","author":"Pellat-Deceunynck","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"20","key":"2022030416215479300_B4","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2022030416215479300_B5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res."},{"issue":"13","key":"2022030416215479300_B6","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2005-02-0563","article-title":"CD8+\u00a0T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden","volume":"106","author":"Goodyear","year":"2005","journal-title":"Blood."},{"issue":"11","key":"2022030416215479300_B7","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med."},{"issue":"4","key":"2022030416215479300_B8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med."},{"issue":"1","key":"2022030416215479300_B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res."},{"issue":"13","key":"2022030416215479300_B10","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2022030416215479300_B11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-18-0198","article-title":"Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma","volume":"7","author":"Cohen","year":"2019","journal-title":"Cancer Immunol Res."},{"issue":"29","key":"2022030416215479300_B12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022030416215479300_B13","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood."},{"issue":"1","key":"2022030416215479300_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"2022030416215479300_B15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic cells revisited","volume":"39","author":"Cabeza-Cabrerizo","year":"2021","journal-title":"Annu Rev Immunol."},{"issue":"2","key":"2022030416215479300_B16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J Immunol."},{"issue":"4","key":"2022030416215479300_B17","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4049\/jimmunol.173.4.2780","article-title":"Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells","volume":"173","author":"Ratzinger","year":"2004","journal-title":"J Immunol."},{"issue":"3","key":"2022030416215479300_B18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.immuni.2008.07.013","article-title":"Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells","volume":"29","author":"Klechevsky","year":"2008","journal-title":"Immunity."},{"issue":"22","key":"2022030416215479300_B19","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1182\/blood-2011-09-382200","article-title":"Human Langerhans cells use an IL-15R-\u03b1\/IL-15\/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1","volume":"119","author":"Romano","year":"2012","journal-title":"Blood."},{"issue":"24","key":"2022030416215479300_B20","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1182\/blood-2011-08-371245","article-title":"The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming","volume":"119","author":"Banchereau","year":"2012","journal-title":"Blood."},{"issue":"17","key":"2022030416215479300_B21","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"2022030416215479300_B22","doi-asserted-by":"crossref","first-page":"e1372081","DOI":"10.1080\/2162402X.2017.1372081","article-title":"Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: results of a phase I vaccine trial","volume":"7","author":"Chung","year":"2017","journal-title":"OncoImmunology."},{"issue":"4","key":"2022030416215479300_B23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt0498-364","article-title":"Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in\u00a0vitro using human dendritic cells transfected with RNA","volume":"16","author":"Nair","year":"1998","journal-title":"Nat Biotechnol."},{"issue":"4","key":"2022030416215479300_B24","first-page":"1028","article-title":"Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells","volume":"60","author":"Boczkowski","year":"2000","journal-title":"Cancer Res."},{"issue":"7","key":"2022030416215479300_B25","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood."},{"issue":"5644","key":"2022030416215479300_B26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science."},{"issue":"1","key":"2022030416215479300_B27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood."},{"issue":"4","key":"2022030416215479300_B28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1349-7006.2008.00738.x","article-title":"MAGE-C1\/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome","volume":"99","author":"Tinguely","year":"2008","journal-title":"Cancer Sci."},{"issue":"2","key":"2022030416215479300_B29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2012-06-435040","article-title":"WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T\u00a0cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions","volume":"121","author":"Tyler","year":"2013","journal-title":"Blood."},{"issue":"13","key":"2022030416215479300_B30","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-10-1820","article-title":"MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin","volume":"17","author":"Nardiello","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2022030416215479300_B31","first-page":"595","article-title":"WT1 expression level and clinical factors in multiple myeloma","volume":"24","author":"Hatta","year":"2005","journal-title":"J Exp Clin Cancer Res."},{"issue":"2","key":"2022030416215479300_B32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2012-06-435040","article-title":"Wilms\u2019 tumor 1 protein-specific T-cell responses in high-risk multiple myeloma patients undergoing T-cell depleted allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion","volume":"121","author":"Tyler","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2022030416215479300_B33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/2326-6066.CIR-13-0174","article-title":"Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma","volume":"2","author":"Tyler","year":"2014","journal-title":"Cancer Immunol Res."},{"issue":"21","key":"2022030416215479300_B34","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-04-0825","article-title":"Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes","volume":"10","author":"Azuma","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2022030416215479300_B35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02983998","article-title":"Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma","volume":"86","author":"Tsuboi","year":"2007","journal-title":"Int J Hematol."},{"issue":"3","key":"2022030416215479300_B36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2307\/2533060","article-title":"Optimal sample size for a series of pilot trials of new agents","volume":"52","author":"Yao","year":"1996","journal-title":"Biometrics."},{"issue":"6","key":"2022030416215479300_B37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.10416","article-title":"CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues","volume":"99","author":"Jungbluth","year":"2002","journal-title":"Int J Cancer."},{"issue":"1","key":"2022030416215479300_B38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1479-5876-11-166","article-title":"Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy","volume":"11","author":"Chung","year":"2013","journal-title":"J Transl Med."},{"issue":"12","key":"2022030416215479300_B39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv."},{"issue":"3","key":"2022030416215479300_B40","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI71691","article-title":"T cell repertoire following autologous stem cell transplantation for multiple sclerosis","volume":"124","author":"Muraro","year":"2014","journal-title":"J Clin Invest."},{"issue":"13","key":"2022030416215479300_B41","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/0008-5472.CAN-15-3173","article-title":"Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects","volume":"76","author":"Sheikh","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"2022030416215479300_B42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2022030416215479300_B43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood."},{"issue":"8","key":"2022030416215479300_B44","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1084\/jem.20052136","article-title":"Enhancement of clonogenicity of human multiple myeloma by dendritic cells","volume":"203","author":"Kukreja","year":"2006","journal-title":"J Exp Med."},{"issue":"12","key":"2022030416215479300_B45","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+\u00a0T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022030416215479300_B46","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2009-06-228676","article-title":"Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+\u00a0T cells and characterize the progression of MGUS to multiple myeloma","volume":"115","author":"Racanelli","year":"2010","journal-title":"Blood."},{"issue":"15","key":"2022030416215479300_B47","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood."},{"issue":"11","key":"2022030416215479300_B48","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother."},{"issue":"10","key":"2022030416215479300_B49","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3109\/10428194.2013.778409","article-title":"Macrophages in multiple myeloma: emerging concepts and therapeutic implications","volume":"54","author":"Asimakopoulos","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"16","key":"2022030416215479300_B50","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood."},{"issue":"7","key":"2022030416215479300_B51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv."},{"key":"2022030416215479300_B52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-142130","article-title":"Describing the cellular and humoral immune tumor microenvironment and malignant transcriptome across the multiple myeloma disease spectrum","volume":"136","author":"Visram","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2022030416215479300_B53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia."},{"issue":"11","key":"2022030416215479300_B54","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood."},{"issue":"6476","key":"2022030416215479300_B55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1547\/1877392\/advancesadv2021005941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1547\/1877392\/advancesadv2021005941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T16:59:33Z","timestamp":1646413173000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/5\/1547\/483748\/Langerhans-dendritic-cell-vaccine-bearing-mRNA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005941","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}